TRAIL induces death of human oligodendrocytes isolated from adult brain

被引:54
作者
Matysiak, M
Jurewicz, A
Jaskolski, D
Selmaj, K
机构
[1] Med Univ Lodz, Dept Neurol, PL-90153 Lodz, Poland
[2] Med Univ Lodz, Dept Neurosurg, PL-90153 Lodz, Poland
关键词
TRAIL; oligodendrocytes; glial cells; death receptor; brain;
D O I
10.1093/brain/awf254
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) has been reported to induce apoptosis in various tumour cell lines and, recently, also in normal cells. TRAIL interacts with four receptors: two signalling receptors (TRAIL-R1 and TRAIL-R2) and two decoy receptors (TRAIL-R3 and TRAIL-R4). We have shown that both signalling receptors are present on the surface of oligodendrocytes isolated from adult human brain (ahOL), whereas the decoy receptors are expressed at a low level on ahOL. TRAIL induces ahOL apoptosis-as characterized by Annexin V staining prior to propidium iodide cell uptake-under conditions of protein synthesis inhibition. However, pre-treatment of ahOL with interferon gamma (IFNgamma) evoked susceptibility to TRAIL-induced death, which did not require inhibition of protein synthesis. A blocking experiment with monoclonal antibodies directed against TRAIL-R1 and TRAIL-R2 revealed that TRAIL-R1 is mainly involved in TRAIL-induced apoptosis of ahOL. In contrast to ahOL, microglial cells were completely resistant to cell death induced by TRAIL. Microglial cells had high surface expression of the decoy receptor TRAIL-R3, suggesting that resistance of these glial cells to TRAIL-induced death depends on the presence of the protective effect of TRAIL-R3. Stimulation of microglia with TRAIL increased further expression of TRAIL-R3, but it had no effect on the expression of TRAIL receptors by ahOL. This result may implicate TRAIL as an effector-immune molecule in selective ahOL demise in inflammatory/demyelinating conditions.
引用
收藏
页码:2469 / 2480
页数:12
相关论文
共 41 条
[1]   TRAIL death pathway expression and induction in thyroid follicular cells [J].
Bretz, JD ;
Rymaszewski, M ;
Arscott, PL ;
Myc, A ;
Ain, KB ;
Thompson, NW ;
Baker, JR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (33) :23627-23632
[2]   Mechanisms of immune injury in multiple sclerosis [J].
Brosnan, CF ;
Raine, CS .
BRAIN PATHOLOGY, 1996, 6 (03) :243-257
[3]   Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family [J].
DegliEsposti, MA ;
Smolak, PJ ;
Walczak, H ;
Waugh, J ;
Huang, CP ;
DuBose, RF ;
Goodwin, RG ;
Smith, CA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (07) :1165-1170
[4]  
DSOUZA S, 1995, J NEUROSCI, V15, P7293
[5]   A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors [J].
Duckett, CS ;
Nava, VE ;
Gedrich, RW ;
Clem, RJ ;
VanDongen, JL ;
Gilfillan, MC ;
Shiels, H ;
Hardwick, JM ;
Thompson, CB .
EMBO JOURNAL, 1996, 15 (11) :2685-2694
[6]   Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) [J].
Fanger, NA ;
Maliszewski, CR ;
Schooley, K ;
Griffith, TS .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (08) :1155-1164
[7]  
Griffith TS, 1998, J IMMUNOL, V161, P2833
[8]  
Griffith TS, 1999, J IMMUNOL, V162, P2597
[9]   TRAIL: a molecule with multiple receptors and control mechanisms [J].
Griffith, TS ;
Lynch, DH .
CURRENT OPINION IN IMMUNOLOGY, 1998, 10 (05) :559-563
[10]  
Halaas O, 2000, SCAND J IMMUNOL, V51, P244